HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU CBD Novel Food Applications On Hold As EFSA Considers Health Risks

Executive Summary

All European Union CBD novel food applications have been paused by EFSA after its Panel on Nutrition, Novel Foods and Food Allergens raised concerns about the ingredient's safety, pointing in a wide-ranging scientific literature review to a number of data gaps related to bioavailability, liver damage, gastrointestinal issues and possible negative impacts on pregnancy and reproductive health.  

You may also be interested in...



UK FSA Finalizes Public CBD List Comprising Almost 12,000 Products

The UK Food Standards Agency has published the final update to its public CBD list following what Canna Consultants' Matt Lawson describes as a regulatory “baptism of fire.” There are now 11,908 products permitted to remain on the UK market once those classed as “removed” are taken into account. These products will either progress to the “validated” stage of the UK's novel food process or also be removed.
 

CBD Supplements Safety: EU Two Years Behind UK

When it comes to assessing the safety of CBD in foods, the EU appears to be lagging behind the UK. Food Standards Agency CEO Emily Miles has noted that EFSA recently reached the same conclusions as the UK’s Committee on Toxicity did two years ago: there are still evidence gaps relating to CBD as a food. This may reassure UK operators that with the FSA further along in the assessment process it will not follow EFSA in suspending CBD novel food applications - but as expert Greer Deal notes, it's too soon to say. 

Hemp Roundtable Says Safety Study Data Should Convince Congress On Lawful CBD Use

Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel